GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Drugs Made In America Acquisition II DMII · USD

N/A · US listing · 🇺🇸 United States

Compare

10.23

+0.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Drugs Made In America Acquisition II

From its filings with the US Securities and Exchange Commission

SEC filings

Drugs Made In America Acquisition II is based in New York, New York. Its shares trade on Nasdaq under the ticker DMII. The SEC classifies its business as blank checks. In the fiscal year to 31 December 2025, it reported net income of $4.2m. At that date it held total assets of $505.0m and shareholders' equity of −$17.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
25 Sept 2025
Employees
2
Head office
420 LEXINGTON AVENUE, NEW YORK, NY, 10170
Classification
Blank Checks
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Ms. Lynn StockwellExecutive Chairman of the Board, Chief Executive Officer, since 2024
  • Mr. Saleem ElmasriChief Financial Officer, Principal Financial and Accounting Officer
  • Mr. Glenn WormanChief Financial Officer, Principal Financial and Accounting Officer, since 2025
  • Dr. Catherine DoIndependent Director
  • Dr. G. Sridhar PrasadIndependent Director
  • Mr. Myron ShulganIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company is a blank check company focused on the pharmaceutical industry.
  • It has a clear mandate to effect a business combination with one or more businesses.
  • It is headquartered in Fort Lauderdale, Florida.

Weaknesses

  • The firm is neither engaged in any operations nor generated any revenues.
  • It has only two employees.
  • It operates in an industry marked as N/A.

Opportunities

  • The firm intends to search for business combination targets in the pharmaceutical industry.
  • It can effect a merger, share exchange, or asset acquisition.
  • It can pursue a share purchase, recapitalization, or reorganization.

Threats

  • The company went IPO on 2025-09-25.
  • It is a US-based company with no current revenue.
  • It has a minimal workforce of only two employees.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.